http://purl.org/np/RAuK2SpdSrihmtW-VW1AcZGZP1hr4oW30pnWBV-AEakLs#Head http://purl.org/np/RAuK2SpdSrihmtW-VW1AcZGZP1hr4oW30pnWBV-AEakLs http://www.nanopub.org/nschema#hasAssertion http://purl.org/np/RAuK2SpdSrihmtW-VW1AcZGZP1hr4oW30pnWBV-AEakLs#assertion http://purl.org/np/RAuK2SpdSrihmtW-VW1AcZGZP1hr4oW30pnWBV-AEakLs http://www.nanopub.org/nschema#hasProvenance http://purl.org/np/RAuK2SpdSrihmtW-VW1AcZGZP1hr4oW30pnWBV-AEakLs#provenance http://purl.org/np/RAuK2SpdSrihmtW-VW1AcZGZP1hr4oW30pnWBV-AEakLs http://www.nanopub.org/nschema#hasPublicationInfo http://purl.org/np/RAuK2SpdSrihmtW-VW1AcZGZP1hr4oW30pnWBV-AEakLs#pubinfo http://purl.org/np/RAuK2SpdSrihmtW-VW1AcZGZP1hr4oW30pnWBV-AEakLs http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.nanopub.org/nschema#Nanopublication http://purl.org/np/RAuK2SpdSrihmtW-VW1AcZGZP1hr4oW30pnWBV-AEakLs#assertion http://purl.obolibrary.org/obo/DOID_11199 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Disease http://purl.org/np/RAuK2SpdSrihmtW-VW1AcZGZP1hr4oW30pnWBV-AEakLs#association http://www.w3.org/1999/02/22-rdf-syntax-ns#object http://purl.obolibrary.org/obo/DOID_11199 http://purl.org/np/RAuK2SpdSrihmtW-VW1AcZGZP1hr4oW30pnWBV-AEakLs#association http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate https://w3id.org/biolink/vocab/treats http://purl.org/np/RAuK2SpdSrihmtW-VW1AcZGZP1hr4oW30pnWBV-AEakLs#association http://www.w3.org/1999/02/22-rdf-syntax-ns#subject https://identifiers.org/drugbank:DB00136 http://purl.org/np/RAuK2SpdSrihmtW-VW1AcZGZP1hr4oW30pnWBV-AEakLs#association http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement http://purl.org/np/RAuK2SpdSrihmtW-VW1AcZGZP1hr4oW30pnWBV-AEakLs#association http://www.w3.org/2000/01/rdf-schema#label predialysis patients calcitriol oral solution is indicated in the management of secondary hyperparathyroidism and resultant metabolic bone disease in patients with moderate to severe chronic renal failure ccr 15 to 55 ml min not yet on dialysis in children the creatinine clearance value must be corrected for a surface area of 1 73 square meters a serum ipth level of 1 pg ml is strongly suggestive of secondary hyperparathyroidism dialysis patients calcitriol oral solution is indicated in the management of hypocalcemia and the resultant metabolic bone disease in patients undergoing chronic renal dialysis in these patients calcitriol oral solution administration enhances calcium absorption reduces serum alkaline phosphatase levels and may reduce elevated parathyroid hormone levels and the histological manifestations of osteitis fibrosa cystica and defective mineralization hypoparathyroidism patients calcitriol oral solution is also indicated in the management of hypocalcemia and its clinical manifestations in patients with postsurgical hypoparathyroidism idiopathic hypoparathyroidism and pseudohypoparathyroidism http://purl.org/np/RAuK2SpdSrihmtW-VW1AcZGZP1hr4oW30pnWBV-AEakLs#association https://w3id.org/biolink/vocab/association_type https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation http://purl.org/np/RAuK2SpdSrihmtW-VW1AcZGZP1hr4oW30pnWBV-AEakLs#association https://w3id.org/biolink/vocab/provided_by https://w3id.org/um/NeuroDKG http://purl.org/np/RAuK2SpdSrihmtW-VW1AcZGZP1hr4oW30pnWBV-AEakLs#association https://w3id.org/biolink/vocab/relation https://w3id.org/um/neurodkg/SymptomaticReliefIndication https://identifiers.org/drugbank:DB00136 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Drug http://purl.org/np/RAuK2SpdSrihmtW-VW1AcZGZP1hr4oW30pnWBV-AEakLs#provenance http://purl.org/np/RAuK2SpdSrihmtW-VW1AcZGZP1hr4oW30pnWBV-AEakLs#assertion http://www.w3.org/ns/prov#wasAttributedTo https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAuK2SpdSrihmtW-VW1AcZGZP1hr4oW30pnWBV-AEakLs#pubinfo http://purl.org/np/RAuK2SpdSrihmtW-VW1AcZGZP1hr4oW30pnWBV-AEakLs#sig http://purl.org/nanopub/x/hasAlgorithm RSA http://purl.org/np/RAuK2SpdSrihmtW-VW1AcZGZP1hr4oW30pnWBV-AEakLs#sig http://purl.org/nanopub/x/hasPublicKey MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB http://purl.org/np/RAuK2SpdSrihmtW-VW1AcZGZP1hr4oW30pnWBV-AEakLs#sig http://purl.org/nanopub/x/hasSignature Qa9CCDGxt0tiC2GborRIpO8j1+HdNNlOz0WOl14qSvVku8CujA9oWO4BVs/9+3hLEbIiIQ4+pG1gaprTtwAPdehJN3fb890+h1G3w/twuK/i85W/Len3Z2x5py6S9PM8OxIHYXWyOC9CGlIKvGZ395GB8k67y/oZYs9Lh6tAdNc= http://purl.org/np/RAuK2SpdSrihmtW-VW1AcZGZP1hr4oW30pnWBV-AEakLs#sig http://purl.org/nanopub/x/hasSignatureTarget http://purl.org/np/RAuK2SpdSrihmtW-VW1AcZGZP1hr4oW30pnWBV-AEakLs http://purl.org/np/RAuK2SpdSrihmtW-VW1AcZGZP1hr4oW30pnWBV-AEakLs http://purl.org/dc/terms/created 2021-07-03T12:15:58.917+02:00 http://purl.org/np/RAuK2SpdSrihmtW-VW1AcZGZP1hr4oW30pnWBV-AEakLs http://purl.org/dc/terms/creator https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAuK2SpdSrihmtW-VW1AcZGZP1hr4oW30pnWBV-AEakLs https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM http://purl.org/np/RAuK2SpdSrihmtW-VW1AcZGZP1hr4oW30pnWBV-AEakLs https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM http://purl.org/np/RAuK2SpdSrihmtW-VW1AcZGZP1hr4oW30pnWBV-AEakLs https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs